279 related articles for article (PubMed ID: 25240824)
1. The evolving field of kinase inhibitors in thyroid cancer.
Marotta V; Sciammarella C; Vitale M; Colao A; Faggiano A
Crit Rev Oncol Hematol; 2015 Jan; 93(1):60-73. PubMed ID: 25240824
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
3. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
Wang E; Karedan T; Perez CA
Anticancer Drugs; 2015 Aug; 26(7):689-97. PubMed ID: 25974026
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
5. Novel molecular targeted therapies for refractory thyroid cancer.
Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
[TBL] [Abstract][Full Text] [Related]
6. Thyroid carcinoma, version 2.2014.
Tuttle RM; Haddad RI; Ball DW; Byrd D; Dickson P; Duh QY; Ehya H; Haymart M; Hoh C; Hunt JP; Iagaru A; Kandeel F; Kopp P; Lamonica DM; Lydiatt WM; McCaffrey J; Moley JF; Parks L; Raeburn CD; Ridge JA; Ringel MD; Scheri RP; Shah JP; Sherman SI; Sturgeon C; Waguespack SG; Wang TN; Wirth LJ; Hoffmann KG; Hughes M
J Natl Compr Canc Netw; 2014 Dec; 12(12):1671-80; quiz 1680. PubMed ID: 25505208
[TBL] [Abstract][Full Text] [Related]
7. Novel therapies for thyroid cancer.
Krajewska J; Jarzab B
Expert Opin Pharmacother; 2014 Dec; 15(18):2641-52. PubMed ID: 25318585
[TBL] [Abstract][Full Text] [Related]
8. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Ye X; Zhu Y; Cai J
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
[TBL] [Abstract][Full Text] [Related]
9. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
10. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
11. Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
Takami HE
Endocr J; 2011; 58(3):151-3. PubMed ID: 21383525
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI
Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730
[TBL] [Abstract][Full Text] [Related]
13. The discovery and development of sorafenib for the treatment of thyroid cancer.
White PT; Cohen MS
Expert Opin Drug Discov; 2015 Apr; 10(4):427-39. PubMed ID: 25662396
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
Felicetti F; Nervo A; Piovesan A; Berardelli R; Marchisio F; Gallo M; Arvat E
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1093-1098. PubMed ID: 28988510
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in metastatic thyroid cancer: a systematic review.
Thomas L; Lai SY; Dong W; Feng L; Dadu R; Regone RM; Cabanillas ME
Oncologist; 2014 Mar; 19(3):251-8. PubMed ID: 24563075
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
20. Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies.
Elia G; Ferrari SM; Ragusa F; Paparo SR; Mazzi V; Ulisse S; Benvenga S; Antonelli A; Fallahi P
Expert Opin Pharmacother; 2022 Apr; 23(5):599-610. PubMed ID: 35038965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]